CLAIMS

That which is claimed is:

1. A pharmaceutical composition comprising Bumetanide Dibenzylamide and one or more solubilizers.

2. The composition of claim 1, wherein the composition comprises about 2.5 mg/mL to about 42 mg/mL of Bumetanide Dibenzylamide.

3. The composition of claim 1 or 2, wherein the composition comprises about 0.25%w/w to about 15%w/w of Bumetanide Dibenzylamide.

4. The composition of claim 1-3, wherein the composition comprises about 0.1%w/w to about 99.75%w/w of one or more solubilizers.

5. The composition of any one of claims 1–4, wherein the one or more solubilizers are selected from the group consisting of short chain triglycerides, long chain triglycerides, and combinations thereof.

6. The composition of any one of claims 1–5, wherein the one or more solubilizers are selected from the group consisting of Polyoxyl 35 Castor Oil, Glyceryl Monolinoleate, and any combination thereof.

7. The composition of any one of claims 1–6, wherein the one or more solubilizers are selected from the group consisting of Caprylocaproyl Polyoxylglycerides, Phosphatidylcholine, Caprylic/Capric Triglyceride, Lauroyl Plyoxyl-32 Glycerides, Sorbitan Ester, and any combination thereof.

8. The composition of any one of claims 1–7, wherein the one or more solubilizers are selected from the group consisting of Ethanol, Propylene Glycol, Polyethylene Glycol 600, Polyethylene Glycol 3350, Oleyl Alcohol, and any combination thereof.

9. The composition of any one of claims 1–7, wherein the one or more solubilizers are selected from the group consisting of PEG-400, Vitamin E TPGS, and any combination thereof.

10. The composition of any one of claims 1–9, wherein at least one of the one or more solubilizers is soybean oil.

11 The composition of any one of claims 1–10, wherein the composition comprises water.

12. The composition of any one of claims 1–11, wherein the one or more solubilizers are selected from the group consisting of Polyvinylpyrrolidone (K30), Poloxamer 407 (P407), Sodium Carboxymethyl cellulose (CMC), and any combination thereof.

13. The composition of any one of claims 1-12, further comprising at least one super disintegrant.

14. The composition of any one of claims 1-13, further comprising at least one wetting agent.

15. The composition of any one of claims 1-14, further comprising at least one surfactant.

16. The composition of any one of claims 1–15, wherein the composition comprises Ceolus KG (microcrystalline cellulose), Mannogem EZ (spray dried mannitol), Polyplasdone XL (super disintegrant), Poloxamer 407, Lauroyl Polyoxyl-32 Glycerides, Sorbitan Ester, Neusilin US2 (magnesium aluminometasilicate), Citric acid Monohydrate, Cabosil M5P (fumed silica), Magnesium Stearate, or any sub-combination thereof.

17. A pharmaceutical composition of any one of claims 1-16, comprising about 1.79 %w/w of Bumetanide Dibenzylamide, about 33.48 %w/w of Polyoxyl 35 Castor oil, about 32.37 %w/w of Glyceryl Monolinoleate, and about 32.37 %w/w of Soybean oil.

18. A pharmaceutical composition of any one of claims 1-16, comprising about 1.76 %w/w of Bumetanide Dibenzylamide, about 32.93 %w/w of Polyoxyl 35 Castor oil, about 31.83 %w/w of Glyceryl Monolinoleate, about 31.83 %w/w of Soybean oil, and about 10.37 %w/w of Ethanol.

19. A pharmaceutical composition of any one of claims 1-16, comprising about 1.59 %w/w of Bumetanide Dibenzylamide, about 22 %w/w of Phosphatidylcholine, about 70 %w/w of Caprylocaproyl Polyoxylglycerides, and about 6.41 %w/w of Caprylic/Capric Triglyceride.

20. A pharmaceutical composition of any one of claims 1-16, comprising about 1.98 %w/w of Bumetanide Dibenzylamide, about 19.39 %w/w of Lauroyl Plyoxyl-32 Glycerides, about 37.62 %w/w of Sorbitan Ester, and about 41.01 %w/w of Soybean oil.

21. A pharmaceutical composition of any one of claims 1-16, comprising about 1.98 %w/w of Bumetanide Dibenzylamide, about 39.72 %w/w of Caprylocaproyl Polyoxylglycerides, about 25.94 %w/w of Sorbitan Ester, and about 49.78 %w/w of Soybean oil.

22. A pharmaceutical composition of any one of claims 1-16, comprising about 1.73 %w/w of Bumetanide Dibenzylamide, about 32.40 %w/w of Polyoxyl 35 Castor oil, about 31.32 %w/w of Glyceryl Monolinoleate, about 31.32 %w/w of Soybean oil, and about 3.24 %w/w of Ethanol.

23. A pharmaceutical composition of any one of claims 1-16, comprising about 1.7 %w/w of Bumetanide Dibenzylamide, about 31.91 %w/w of Polyoxyl 35 Castor oil, about 30.85 %w/w of Glyceryl Monolinoleate, about 30.85 %w/w of Soybean oil, and about 4.68 %w/w of Ethanol.

24. The pharmaceutical composition of any one of claims 1 – 23, comprising about 10 %w/w to about 100 %w/w of Caprylocaproyl Polyoxylglycerides.

25. The pharmaceutical composition of any one of claims 1 – 24, comprising about 12 %w/w to about 20 %w/w of Propylene Glycol.

26. The pharmaceutical composition of any one of claims 1 – 25 comprising about 57 %w/w to about 80 %w/w of PEG 400.

27. The pharmaceutical composition of any one of claims 1 – 26 comprising about 1% Vitamin E TPGS.

28. A pharmaceutical composition of any one of the claims 1- 27, comprising about 2.73 %w/w of Bumetanide Dibenzylamide, about 10 % w/w of Caprylocaproyl Polyoxylglycerides, about 12.05 %w/w of Propylene Glycol, about 67.22 %w/w of Polyethylene Glycol 400, and about 8 %w/w of Water.

29. A pharmaceutical composition of any one of the claims 1- 27, comprising about 2.82 %w/w of Bumetanide Dibenzylamide, about 4.65 % w/w of Caprylocaproyl Polyoxylglycerides, about 13.01 %w/w of Propylene Glycol, about 67.97 %w/w of Polyethylene Glycol 400, about 0.92 %w/w Polyvinylpyrrolidone (K30), and about 10.62 %w/w of Water.

30. A pharmaceutical composition of any one of the claims 1- 27, comprising about 0.6 %w/w of Bumetanide Dibenzylamide, about 10 %w/w of Caprylocaproyl Polyoxylglycerides, about 9.15 %w/w of Propylene Glycol, about 53.84 %w/w of Polyethylene Glycol 400, about 3.6 %w/w of Polyvinylpyrrolidone (K30), about 2.4 %w/w of Poloxamer 407 (P407), about 0.41 %w/w Sodium CMC, and about 20 %w/w of water.

31. A pharmaceutical composition of any one of the claims 1- 27, comprising about 0.6 %w/w of Bumetanide Dibenzylamide, about 10 %w/w of Caprylocaproyl Polyoxylglycerides, about 9.15 %w/w of Propylene Glycol, about 66.75 %w/w of Polyethylene Glycol 400, about 3.6 %w/w of Polyvinylpyrrolidone (K30), about 2.4 %w/w of Poloxamer 407 (P407), and about 7.5 %w/w of Polyethylene Glycol 3350.

32. A pharmaceutical composition of any one of the claims 1- 27, comprising about 15 %w of Bumetanide Dibenzylamide, about 20 %w of Microcrystalline Cellulose, about 51 %w of Spray Dried Mannitol, about 7 %w of Polyplasdone XL (super disintegrate), about 3% w of Poloxamer 407, about 1.5 %w of Citric Acid Monohydrate, about 1.0 %w of Cabosil M5P (fumed silica), and about 1.5 %w of Magnesium Stearate.

33. A pharmaceutical composition of any one of the claims 1- 27, comprising about 7.4 %w of Bumetanide Dibenzylamide, about 9.9 %w of Lauroyl Plyoxyl-32 Glycerides, about 9.9 %w of Sorbitan Ester, about 54.3 %w of Polyplasdone XL (super disintegrate), about 0.5% w of Poloxamer 407, about 0.7 %w of Citric Acid Monohydrate, about 2.0 %w of Cabosil M5P (fumed silica), about 14.8 %w of Neusilin US2 (magnesium aluminometasilicate), and about 0.5 %w of Magnesium Stearate.

34. A pharmaceutical composition comprising of any one of the claims 1- 27, a vehicle composition comprising 55 % Polyethylene Glycol 400 (PEG-400) in water, or 41 % PEG-400,

12 % Ethanol, 47 % water or 45 % PEG-400, 10 % DMSO, 45 % water, or 31 % PEG-400, 31 % Tetraglycol, 15 % Caprylocaproyl Polyoxylglycerides, 23 % water, or 30 % PEG-400, 10 % N-Methyl Pyrrolidone, 10 % DMSO, 50 % water, or 25 % PEG-400, 10 % DMSO, 20 % Tetraglycol, 45 % water, or 20 % Ethanol in water, or 20% Hydroxypropyl-β-Cyclodextrin in water, or 11% DMSO, 22% PEG-400, 22% Tetraglycol, 44% water, or 44% PEG-400, 0.4% Poloxamer-188, 22% N-Methyl Pyrrolidone, 33% water, or 20% PEG-400, 15% Hydroxypropyl-β-Cyclodextrin in water, or 40% PEG-400, 20% Propylene Glycol, 5% Ethanol and 35%, water.

35. A pharmaceutical composition of any one of the claims 1- 27, comprising about 28 g of Bumetanide Dibenzylamide, and about 3 ml of a solvent, wherein 50 g of solvent comprises about 5g of Caprylocaproyl Polyoxylglycerides, about 10g of Propylene Glycol, about 28.5g of PEG-400, about 0.5g of Vitamin E TPGS, about 1g of Ethanol, and about 4.5g of water.

36. A method for treating a patient in need thereof comprising:

administering a pharmaceutical composition comprising Bumetanide Dibenzylamide and one or more solubilizers.

37. The method of claim 36, wherein the pharmaceutical composition comprises about 2.5 mg/mL to about 42 mg/mL of Bumetanide Dibenzylamide.

38. The method of any one of the claims 36-37, wherein the pharmaceutical composition comprises about 0.25%w/w to about 15%w/w of Bumetanide Dibenzylamide.

39. The method of any one of the claims 36-38, wherein the one or more solubilizers comprise short chain triglycerides, long chain triglycerides, or combinations thereof.

40. The method of any one of the claims 36-39, wherein the composition comprises about 0.1%w/w to about 99.75%w/w of one or more solubilizers

41. The method of any one of the claims 36-40, wherein the one or more solubilizers comprise polyoxyl 35 castor oil, Glyceryl Monolinoleate, or any combination thereof.

42. The method of any one of the claims 36-41, wherein the one or more solubilizers comprise Caprylocaproyl Polyoxylglycerides, Phosphatidylcholine, Caprylic/Capric Triglyceride, Lauroyl Plyoxyl-32 Glycerides, Sorbitan Ester or any combination thereof.

43. The method of any one of the claims 36-42, wherein the one or more solubilizers comprise Ethanol, Propylene Glycol, Polyethylene Glycol 600, Polyethylene Glycol 3350, Oleyl Alcohol, or any combination thereof.

44. The method of any one of the claims 36-43, wherein the one or more solubilizers comprise PEG-400, Vitamin E TPGS, or any combination thereof.

45. The method of any one of the claims 36-44, wherein the one or more solubilizers comprises Soybean oil.

46. The method of any one of the claims 36-45, wherein the one or more solubilizers comprises water.

47. The method of any one of the claims 36-46, wherein the one or more solubilizers comprise Polyvinylpyrrolidone (K30), Poloxamer 407 (P407), Sodium Carboxymethyl cellulose (CMC), or any combination thereof.

48. The method of any one of the claims 36-47, wherein the one or more solubilizers comprises at least one super disintegrant.

49. The method of any one of the claims 36-48, wherein the one or more solubilizers comprises at least one wetting agent.

50. The method of any one of the claim 36-49, wherein the one or more solubilizers comprises at least one surfactant.

51. The method of any one of the claim 36-50, wherein the one or more solubilizers comprises Ceolus KG (microcrystalline cellulose), Mannogem EZ (spray dried mannitol), Polyplasdone XL (super disintegrant), Poloxamer 407, lauroyl plyoxyl-32 glycerides, sorbitan ester, Neusilin US2 (magnesium aluminometasilicate), Citric acid Monohydrate, Cabosil M5P (fumed silica), Magnesium Stearate or any combination thereof.

52. The method of claim 36, wherein the pharmaceutical composition comprises about 1.79 %w/w of Bumetanide Dibenzylamide, about 33.48 %w/w of Polyoxyl 35 Castor oil, about 32.37 %w/w of Glyceryl Monolinoleate, and about 32.37 %w/w of Soybean oil.

53. The method of claim 36, wherein the pharmaceutical composition comprises about 1.76 %w/w of Bumetanide Dibenzylamide, about 32.93 %w/w of Polyoxyl 35 Castor oil, about 31.83 %w/w of Glyceryl Monolinoleate, about 31.83 %w/w of Soybean oil, and about 10.37 %w/w of Ethanol.

54. The method of claim 36, wherein the pharmaceutical composition comprises about 1.59 %w/w of Bumetanide Dibenzylamide, about 22 %w/w of Phosphatidylcholine, about 70 %w/w of Caprylocaproyl Polyoxylglycerides, and about 6.41 %w/w of Caprylic/Capric Triglyceride.

55. The method of claim 36, wherein the pharmaceutical composition comprises about 1.98 %w/w of Bumetanide Dibenzylamide, about 19.39 %w/w of Lauroyl Plyoxyl-32 Glycerides, about 37.62 %w/w of Sorbitan Ester, and about 41.01 %w/w of Soybean oil.

56. The method of claim 36, wherein the pharmaceutical composition comprises about 1.98 %w/w of Bumetanide Dibenzylamide, about 39.72 %w/w of Caprylocaproyl Polyoxylglycerides, about 25.94 %w/w of Sorbitan Ester, and about 49.78 %w/w of Soybean oil.

57. The method of claim 36, wherein the pharmaceutical composition comprises about 1.73 %w/w of Bumetanide Dibenzylamide, about 32.40 %w/w of Polyoxyl 35 Castor oil,

about 31.32 %w/w of Glyceryl Monolinoleate, about 31.32 %w/w of Soybean oil, and about 3.24 %w/w of Ethanol.

58. The method of claim 36, wherein the pharmaceutical composition comprises about 1.7 %w/w of Bumetanide Dibenzylamide, about 31.91 %w/w of Polyoxyl 35 Castor oil, about 30.85 %w/w of Glyceryl Monolinoleate, about 30.85 %w/w of Soybean oil, and about 4.68 %w/w of Ethanol.

59. The method of claim 36, wherein the pharmaceutical composition comprises about 10 %w/w to about 100 %w/w of Caprylocaproyl Polyoxylglycerides.

60. The method of claim 36, wherein the pharmaceutical composition comprises about 12 %w/w to about 20 %w/w of Propylene Glycol.

61. The method of claim 36, wherein the pharmaceutical composition comprises about 57 %w/w to about 80 %w/w of PEG 400.

62. The method of claim 36, wherein the pharmaceutical composition comprises about 1% Vitamin E TPGS.

63. The method of claim 36, wherein the pharmaceutical composition comprises about 2.73 %w/w of Bumetanide Dibenzylamide, about 10 % w/w of Caprylocaproyl Polyoxylglycerides, about 12.05 %w/w of Propylene Glycol, about 67.22 %w/w of Polyethylene Glycol 400, and about 8 %w/w of Water.

64. The method of claim 36, wherein the pharmaceutical composition comprises about 2.82 %w/w of Bumetanide Dibenzylamide, about 4.65 % w/w of Caprylocaproyl Polyoxylglycerides, about 13.01 %w/w of Propylene Glycol, about 67.97 %w/w of Polyethylene Glycol 400, about 0.92 %w/w Polyvinylpyrrolidone (K30), and about 10.62 %w/w of Water.

65. The method of claim 36, wherein the pharmaceutical composition comprises about 0.6 %w/w of Bumetanide Dibenzylamide, about 10 %w/w of Caprylocaproyl Polyoxylglycerides, about 9.15 %w/w of Propylene Glycol, about 53.84 %w/w of Polyethylene Glycol 400, about 3.6 %w/w of Polyvinylpyrrolidone (K30), about 2.4 %w/w of Poloxamer 407 (P407), about 0.41 %w/w Sodium CMC, and about 20 %w/w of water.

66. The method of claim 36, wherein the pharmaceutical composition comprises about 0.6 %w/w of Bumetanide Dibenzylamide, about 10 %w/w of Caprylocaproyl Polyoxylglycerides, about 9.15 %w/w of Propylene Glycol, about 66.75 %w/w of Polyethylene Glycol 400, about 3.6 %w/w of Polyvinylpyrrolidone (K30), about 2.4 %w/w of Poloxamer 407 (P407), and about 7.5 %w/w of Polyethylene Glycol 3350.

67. The method of claim 36, wherein the pharmaceutical composition comprises about 15 %w of Bumetanide Dibenzylamide, about 20 %w of Microcrystalline Cellulose, about 51 %w of Spray Dried Mannitol, about 7 %w of Polyplasdone XL (super disintegrate), about 3% w of Poloxamer 407, about 1.5 %w of Citric Acid Monohydrate, about 1.0 %w of Cabosil M5P (fumed silica), and about 1.5 %w of Magnesium Stearate.

68. The method of claim 36, wherein the pharmaceutical composition comprises up to about 17.5%w of Bumetanide Dibenzylamide, about 9.9 %w of Lauroyl Plyoxyl-32 Glycerides, about 9.9 %w of Sorbitan Ester, about 54.3 %w of Polyplasdone XL (super disintegrate), about 0.5% w of Poloxamer 407, about 0.7 %w of Citric Acid Monohydrate, about 2.0 %w of Cabosil M5P (fumed silica), about 14.8 %w of Neusilin US2 (magnesium aluminometasilicate), and about 0.5 %w of Magnesium Stearate.

69. The method of claim 36, wherein the pharmaceutical composition comprises a vehicle composition comprising 55 Polyethylene Glycol 400 (PEG-400) in water, or 41 % PEG-400, 12 % ethanol, 47 % water or 45 % PEG-400, 10 % DMSO, 45 % water, or 31 % PEG-400, 31 % Tetraglycol, 15 % Caprylocaproyl Polyoxylglycerides, 23 % water, or 30 % PEG-400, 10 % N-Methyl Pyrrolidone, 10 % DMSO, 50 % water, or 25 % PEG-400, 10 % DMSO, 20 % Tetraglycol, 45 % water, or 20 % Ethanol in water, or 20% Hydroxypropyl-β-Cyclodextrin in water, or 11% DMSO, 22% PEG-400, 22% Tetraglycol, 44 % water, or 44 % PEG-400, 0.4 % Poloxamer-188, 22 % N-Methyl pyrrolidone, 33 % water, or 20 % PEG-400, 15 % Hydroxypropyl-β-Cyclodextrin in water, or 40 % PEG-400, 20 % Propylene Glycol, 5% Ethanol, and 35% water.

70. The method of claim 36, wherein the pharmaceutical composition comprises about 28 g of Bumetanide Dibenzylamide, and about 3 ml of a solvent, wherein 50 g of solvent comprises about 5g of Caprylocaproyl Polyoxylglycerides, about 10g of Propylene Glycol, about 28.5g of PEG-400, about 0.5g of Vitamin E TPGS, about 1g of Ethanol, and about 4.5g of water.

71. The method of any one of the claims 36-70, wherein the pharmaceutical composition is an oral capsule.

72. The method of any one of the claims 36-70, wherein the pharmaceutical composition is a nasal solution.

73. The method of any one of the claims 36-70, wherein the pharmaceutical composition is a rectal gel.

74. The method of any one of the claims 36-70, wherein the pharmaceutical composition is a rectal paste.

75. The method of any one of the claims 36-70, wherein the pharmaceutical composition is a sublingual tablet.

76. The method of any one of the claims 36-70, wherein the pharmaceutical composition is an injectable composition.

77. The method of any one of the claims 36-70, wherein the administration of the patient with the pharmaceutical composition is done orally.

78. The method of any one of the claims 36-70, wherein the administration of the patient with the pharmaceutical composition is done intranasally.

79. The method of any one of the claims 36-70, wherein the administration of the patient with the pharmaceutical composition is done intrarectally.

80. The method of any one of the claims 36-70, wherein the administration of the patient with the pharmaceutical composition is done sublingually.

81. The method of any one of the claims 36-70, wherein the administration of the patient with the pharmaceutical composition is done subcutaneously.

82. The method of any one of the claims 36-70, wherein the administration of the patient with the pharmaceutical composition is done intramuscularly.

83. A pharmaceutical composition of any one of the claims 1-35, comprising Bumetanide Dibenzylamide and one or more organic anion transport (OAT) inhibitors.

84. The pharmaceutical composition of claim 83, wherein the one or more OAT inhibitors are competitive antagonists.

85. The pharmaceutical composition of claim 84 or 83, wherein the Bumetanide Dibenzylamide and the one or more OAT inhibitors are formulated with different release profiles.

86. The pharmaceutical composition of claim 85, wherein at least one OAT inhibitor is formulated to be released prior to release of the Bumetanide Dibenzylamide.

87. The pharmaceutical compositon of claim 86, wherein at least one OAT inhibitor is formulated to be released prior to the Bumetanide Dibenzylamide achieving maximum plasma concentration (C_{max}) in a patient receving the composition.

88. The pharmaceutical composition of any one of claims 83 to 87, wherein the one or more OAT inhibitor is sleected from the group consisting of probenecid, aspirin, ibuprofen, acetylsalicylic acid, diclofenac, aspartame, and valproic acid.

89. A pharmaceutical composition of any one of the claims 1-35, comprising Bumetanide Dibenzylamide in a self-emulsifying drug delivery system (SEDDS).

90. The pharmaceutical composition of claim 89, wherein the SEDDS further comprises an isotropic mixture of oils, solubilizers, surfactants, and co-solvents.

91. A pharmaceutical compositon comprising Bumetanide Dibenzylamide in an oral lymphatic targeted formulation.

92. A pharmaceutical compositon of any one of the claims 1-35, comprising:

Bumetanide Dibenzylamide,

Polyoxyl 35 Castor Oil (Kolliphor EL),

Glyceryl Monolinoleate (Maisine CC),

Soybean Oil, and

Ethanol.

93. The composition of claim 91 or 92, comprising: about 1 to 2 w/w% Bumetanide Dibenzylamide, about 30 to 35 w/w% Polyoxyl 35 Castor Oil (Kolliphor EL), about 30 to 35 w/w% Glyceryl Monolinoleate (Maisine CC), about 30 to 35 w/w% Soybean Oil, and about 2.5 to 5 w/w% Ethanol.

94. The composition of any one of claims 91 - 93, comprising: 1.7 w/w% Bumetanide Dibenzylamide, about 32.4 w/w% Polyoxyl 35 Castor Oil (Kolliphor EL), about 31.3 w/w% Glyceryl Monolinoleate (Maisine CC), about 31.3 w/w% Soybean Oil, and about 3.2 w/w% Ethanol.

95. A pharmaceutical composition of any one of the claims 1-35, comprising a prodrug of Bumetanide and one or more oral lymphatic targeting excipients.

96. The pharmaceutical composition of claim 95, wherein the prodrug of Bumetanide is an amide prodrug.

97. The pharmaceutical composition of claim 95 or 96, wherein the prodrug of Bumetanide is one or more of Bumetanide Dibenzylamide, Bumetanide Diethylamide, and Bumetanide Morpholinoamide.

98. The pharmaceutical composition of any one of claims 95 - 97, comprising alkoxylated castor oil.

99. The pharmaceutical composition of any one of claims 95 - 97, comprising Polyoxyl 35 Castor Oil (Kolliphor EL).

100. The pharmaceutical composition of any one of claims 95 - 99, comprising one or more of a mono-, di-, and triglyceride.

101. The pharmaceutical composition of any one of claims 95 - 100, comprising Glyceryl Monolinoleate (Maisine CC).

102. The pharmaceutical composition of any one of claims 95 - 101, comprising a fixed oil.

103. The pharmaceutical compositon of any one of claims 95 - 102, comprising soybean oil.

104. The pharmaceutical composition of any one of claims 95 - 103, comprising a water soluable solvent.

105. The pharmaceutical composition of any one of claims 95 - 104, comprising ethanol.

106. The method of any one of the claims 36 - 81, wherein the pharmaceutical composition comprises up to 17.5 %w of Bumetanide Dibenzylamide, about 20 %w solublizer, and about 15 %w absorbant.

107. A method of treating epilepsy comprising administering a compound or composition as defined in any one of claims 1- 106 to a patient in need thereof.

108. A method of treating a seizure disorder comprising administering a compound or composition as defined in any one of claims 1- 106 to a patient in need thereof.

109. A method of treating Alzheimer's Disease comprising administering a compound or composition as defined in any one of claims 1- 106 to a patient in need thereof.